Trinity Biotech (TRIB) AI Stock Analysis

• Market Cap: $16.25M
• Dividend Yield: N/A
• Average Volume (3M): 136.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: -4.35%
• EPS Growth: -6.31%
• Country: US
• Employees: 380
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 18,632,019
• 10 Day Avg. Volume: 159,092
• 30 Day Avg. Volume: 136,139
• PEG Ratio: 0.06
• Price to Book (P/B): -2.25
• Price to Sales (P/S): 1.28
• P/FCF Ratio: -5.54
• Enterprise Value/Market Cap: 6.30
• Enterprise Value/Revenue: 1.88
• Enterprise Value/Gross Profit: 5.85
• Enterprise Value/Ebitda: -5.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $1.00 ▲(12.36% Upside)

Trinity Biotech's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. Technical analysis shows mixed signals, with short-term bullish momentum but potential for a pullback. Valuation metrics are unattractive due to negative earnings and lack of dividends.

Positive Factors

Strategic Manufacturing Shift

The WHO approval for offshored manufacturing is expected to improve gross margins and cash flow, enhancing long-term profitability and competitive positioning.

Product Innovation

The strategic collaboration to enhance the EpiCapture test demonstrates Trinity Biotech's commitment to innovation, potentially expanding its market reach in diagnostics.

Corporate Governance Improvement

Amendments to the Constitution and credit agreement reflect efforts to refine governance and financial strategies, potentially improving operational flexibility.

Negative Factors

Declining Revenue

Declining revenues indicate shrinking sales, which can undermine market position and reduce financial resources for growth and innovation.

High Debt Levels

High debt levels can strain cash flow and limit financial flexibility, posing risks to long-term financial stability and strategic initiatives.

Negative Profit Margins

Consistently negative profit margins reflect operational inefficiencies, challenging the company's ability to sustain profitability and invest in growth.

Trinity Biotech Business Overview & Revenue Model

Company Description

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

How the Company Makes Money

Trinity Biotech generates revenue through the sale of its diagnostic products and services. The company's revenue model is primarily based on the direct sales of its various diagnostic kits and instruments to hospitals, laboratories, and healthcare providers. Key revenue streams include immunoassay products, which are significant contributors to sales, as well as its expanding portfolio in molecular diagnostics. Additionally, Trinity Biotech benefits from partnerships with other companies and healthcare organizations, which can lead to collaborative product development and distribution agreements. The company's focus on research and development allows it to innovate and maintain a competitive edge in the diagnostic market, which further contributes to its earnings.

Trinity Biotech Financial Statement Overview

Summary

Trinity Biotech is experiencing significant financial challenges, with declining revenues and profitability, high debt levels, and negative equity. The company faces risks related to financial stability and sustainability. While there are some improvements in operating cash flows, overall financial health is weak, requiring strategic interventions to restore growth and stability.

Income Statement

Trinity Biotech has been experiencing declining revenues and profitability in recent years. The gross profit margin has decreased, and the company has been running at a net loss, with net profit margins consistently negative. The revenue growth rate is negative, indicating shrinking sales year-over-year. Both EBIT and EBITDA margins have also been negative, reflecting operational inefficiencies and challenges in covering operational costs.

Balance Sheet

The balance sheet shows significant financial distress, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, but high total debt levels are concerning. The equity ratio is negative, highlighting an unsustainable financial structure. Return on equity is negative as well, reflecting ongoing losses.

Cash Flow

Cash flow metrics indicate challenges but also some operational cash inflow improvements in the latest year. Free cash flow remains negative, though the operating cash flow to net income ratio suggests some improvement in cash generation relative to net losses. However, consistent negative free cash flow indicates cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.43M	61.55M	56.83M	62.52M	81.15M	101.98M
Gross Profit	17.49M	21.44M	19.45M	22.05M	33.45M	48.58M
EBITDA	-20.46M	-16.91M	-24.10M	-16.71M	10.59M	3.19M
Net Income	-37.28M	-31.79M	-24.02M	-41.00M	875.00K	-6.39M
Balance Sheet
Total Assets	99.79M	103.29M	59.44M	92.10M	118.89M	130.40M
Cash, Cash Equivalents and Short-Term Investments	4.07M	5.17M	3.69M	6.58M	25.91M	27.33M
Total Debt	107.97M	100.76M	67.43M	72.20M	99.16M	104.34M
Total Liabilities	143.41M	138.47M	83.38M	94.28M	119.21M	132.62M
Stockholders Equity	-43.63M	-35.18M	-23.95M	-2.18M	-319.00K	-2.22M
Cash Flow
Free Cash Flow	-12.99M	-14.26M	-12.36M	-6.90M	4.55M	13.56M
Operating Cash Flow	-4.34M	-4.19M	-11.56M	-921.00K	13.24M	23.75M
Investing Cash Flow	-10.99M	-22.97M	24.76M	-5.98M	-8.69M	-10.20M
Financing Cash Flow	13.78M	28.81M	-16.04M	-12.32M	-6.02M	-2.72M

Trinity Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Negative. The current price of 0.89 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 0.97, and above the 200-day MA of 0.88, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.38 is Neutral, neither overbought nor oversold. The STOCH value of 9.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRIB.

Trinity Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	57 Neutral	$38.88M	-27.67	-9.76%	―	30.95%	59.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INBS	45 Neutral	$5.89M	-3.37	-223.45%	―	3.26%	65.96%
TRIB	40 Underperform	$16.25M	-0.31	―	―	-4.35%	-6.31%
BNGO	40 Underperform	$16.28M	-0.10	-78.22%	―	-13.84%	88.80%
BIAF	38 Underperform	$5.58M	-0.06	-245.18%	―	-27.66%	13.18%
CHEK	26 Underperform	$9.13M	―	―	―	―	―

Trinity Biotech Corporate Events

Trinity Biotech Secures WHO Approval for Offshore Manufacturing of HIV Test

On November 18, 2025, Trinity Biotech announced it received World Health Organization approval for the offshored and outsourced manufacturing of its Uni-Gold rapid HIV test. This approval is a significant milestone in the company’s transformation plan aimed at enhancing profitability. The strategic move to offshore manufacturing is expected to improve gross margins, EBITDA, and cash flow, while maintaining product integrity and compliance. This initiative reflects the leadership’s capability to execute strategic transformations and positions the company for long-term growth by reducing costs and focusing on innovation.

Trinity Biotech Collaborates to Enhance Prostate Cancer Test

On November 14, 2025, Trinity Biotech announced a strategic collaboration with a leading bioinformatics company to enhance the EpiCapture prostate cancer test through advanced epigenetic analysis. This collaboration aims to improve the test’s ability to monitor prostate cancer progression non-invasively, potentially reducing the need for invasive procedures and improving patient care. The EpiCapture test, currently in late-stage development, has shown promise in accurately predicting high-grade cancers and is part of Trinity Biotech’s strategy to expand its portfolio of innovative diagnostic technologies.

Trinity Biotech Amends Constitution and Credit Agreement Following AGM

At the Annual General Meeting on September 30, 2025, Trinity Biotech’s shareholders approved amendments to the company’s Constitution, which were subsequently disclosed. Additionally, the company and its subsidiaries amended their credit agreement with Perceptive Credit Holdings III, L.P., reflecting a strategic financial adjustment. These changes are indicative of Trinity Biotech’s efforts to refine its corporate governance and financial strategies, potentially impacting its operational flexibility and stakeholder relations.

Trinity Biotech Announces AGM Results and Board Changes

On September 30, 2025, Trinity Biotech plc held its annual general meeting where shareholders approved all proposed resolutions with at least 93% of votes. Key resolutions included the re-appointment of Grant Thornton as statutory auditor, authorization for the board to fix auditors’ remuneration, reduction of nominal value of A Ordinary Shares, increase in authorized share capital, and refreshing the board’s authority to issue new shares. Jim Walsh retired from the board but will continue as a Scientific Advisor, highlighting his long-term commitment to the company.